Metoclopramid Slavia (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide works by competitively blocking dopamine D2 receptors in the chemoreceptor trigger zone of the brain and throughout the gastrointestinal tract, which reduces the emetic signal. It also antagonizes 5‑HT3 receptors and has cholinergic activity, together enhancing gastric motility and accelerating stomach emptying.

The appropriate dose of Metoclopramid Slavia is determined by the prescribing clinician based on the patient’s condition, age, renal function and response to therapy. Healthcare professionals follow local prescribing guidelines and adjust the regimen as needed for safety and efficacy.

Safety data for metoclopramide in pregnancy and lactation are limited, and the product’s pregnancy category is not definitively established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the Metoclopramid Slavia product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metoclopramide differs from serotonin‑type antiemetics such as ondansetron by primarily targeting dopamine D2 receptors, offering both anti‑emetic and pro‑kinetic benefits. It is often chosen when gastric motility enhancement is desired, whereas agents like ondansetron focus solely on serotonin pathways and lack pro‑kinetic activity.

Metoclopramid Slavia should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity to maintain its stability.

Metoclopramid Slavia is taken orally, usually as a tablet. It is commonly administered 30 minutes before meals and at bedtime, but the exact timing and frequency are determined by the prescribing clinician based on the therapeutic indication and patient response.

The most serious adverse reactions include extrapyramidal symptoms such as acute dystonia, tardive dyskinesia with long‑term use, neuroleptic malignant syndrome, severe depression or suicidal thoughts, and rare cardiac arrhythmias. Patients should seek immediate medical attention if they experience uncontrolled muscle movements, severe mood changes or cardiac symptoms.

Metoclopramid Slavia should be avoided in individuals with known hypersensitivity to metoclopramide or any component of the formulation, in patients with pheochromocytoma, seizure disorders, or severe depression, and in children under 18 years unless specifically indicated. Caution is also advised for patients with Parkinson’s disease or other dopamine‑dependent conditions.